Trial Profile
A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 598809 (Primary)
- Indications Eating disorders; Smoking withdrawal; Substance-related disorders
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 15 May 2014 New trial record